Watchlist

Watchlist
Adamas Pharmaceuticals, Inc. (ADMS)
Adamas Pharmaceuticals, Inc. (ADMS)
Premarket analyst action - healthcare
Cellectis S.A. (NASDAQ: CLLS ) initiated with Buy rating and $50 (76% upside) price target at Barclays. Shares up 8% premarket. More news on: Cellectis S.A., Aptinyx, AVROBIO, Healthcare stocks news, Stocks on the move, , Read more …
Adamas Pharmaceuticals, Inc. (ADMS)